Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00092
|
|||||
| Drug Name |
Teriflunomide
|
|||||
| Synonyms |
(2Z)-2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxobutanenitrile; (Z)-2-Cyano-alpha'alpha'alpha-trifluoro-3-hydroxy-p-crotonotoluidide; 2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide; 2-hydroxyethylidene-cyanoacetic acid-4-trifluoromethyl anilide; A 771726; A-771726; Active metabolite of leflunomide; Flucyamide; HMR 1726; HMR-1726; N-(4-Trifluoromethylphenyl)-2-cyano-2-hydroxycrotonamide; RS 61980; RS-61980; SU 20; SU-0020; Teriflunomide [INN]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Multiple scierosis [ICD11: 8A40] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C12H9F3N2O2
|
|||||
| Canonical SMILES |
CC(=C(C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O
|
|||||
| InChI |
InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-
|
|||||
| InChIKey |
UTNUDOFZCWSZMS-YFHOEESVSA-N
|
|||||
| CAS Number |
CAS 163451-81-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 270.21 | Topological Polar Surface Area | 73.1 | ||
| Heavy Atom Count | 19 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
3.3
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103252419
, 103929187
, 104304838
, 104633246
, 113986292
, 12014666
, 131294182
, 134223898
, 134338701
, 134338970
, 134340294
, 134340452
, 135074184
, 135263629
, 135626890
, 137116564
, 143267135
, 152134192
, 15221873
, 160645856
, 162254943
, 163414519
, 163620868
, 163686197
, 164178177
, 164835947
, 17182873
, 172919649
, 175266318
, 176251501
, 178103450
, 180100588
, 180371831
, 187072836
, 198993049
, 29223012
, 32961983
, 36887811
, 39470329
, 49896832
, 53790606
, 57363933
, 605680
, 77206778
, 77206779
, 77206780
, 8020778
, 836841
, 93311044
, 99311205
|
|||||
| ChEBI ID |
CHEBI:68540
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | Leflunomide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | MDR-ABC transporters: biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):779-87. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.